lead to hanging, so the use of 1 degree paint slightly thicker, 2 degree paint completely cover primer this construction method can effectively control the total thickness of the coating and avoid hanging defects
An IDH1/2 wild WHO IV. class diffuse star cell glue with GBM molecular characteristics...
Time of Update: 2020-10-23
results compared 71 patients with IDH1/2 wild WHO IV.class glioma with typical clinical, imaging and histological characteristics of LGG with OS in 197 patients with IDH1/2 wild glioblastoma.
Bayer Adempas is used for clinical success in phase IV in underreacted PAH patients treated with PDE5i.
Time of Update: 2020-09-27
using blind methods, and clinical deterioration events were independently determined. , the most common adverse events (AEs) in the study were usually consistent with what was seen in the critical study PATENT. Bayer, a 12-week multi-center
Ultra-sensitive detection method to detect THE activity of POP-IV in complex biological samples.
Time of Update: 2020-09-14
peptide enzyme-IV (DPP-IV, CD26), which is used in the active detection of DPP-IV in human blood and tissues, as well as in the study of target enzyme function imaging at the biogenics and tissue levels, the results of which were published
Interpretation of Japan's New Food Labeling Law (IV)
Time of Update: 2020-09-03
this article will introduce the new Food Labeling Benchmark food and health food classification methods, nutrient labeling methods and nutrition enhancement claims rules and other content. First, the Japanese Food and Health Food
Domestic PD-L1 antibodies! Keystone Pharmaceutical CS1001 first-line treatment iv stage NON-small
Time of Update: 2020-08-26
Phase III clinical trial CS1001-302 in patients with NSCLC, in the planned mid-term analysis, was evaluated by the Independent Data Monitoring Committee (iDMC) and reached the preset main research endpoint, the results were statistically significant
Keystone Pharmaceuticals' anti-PD-L1 mono-anti-CS1001 treatment of Phase IV non-small cell lung
Time of Update: 2020-08-16
treatment in stage IV squamous and non-scaly non-small cell lung cancer (NSCLC) two tissue subtypes of patients in the phase of randomized double-blind III clinical trial analysis showed that CS1001 combined chemotherapy significantly prolonged
Gastroenterology: Study on the prevalence of functional bowel disease that meets Rome IV standards
Time of Update: 2020-06-23
Recently, researchers conducted a cross-country study to examine the prevalence, distribution and effects of patients with functional bowel disease (FBD) that met the Rome IV standard.
Intravenous (IV) and oral omadacycline or approved in October
Time of Update: 2020-06-11
the project included three completed phase 3 studies assessing the safety and efficacy of daily IV and oral omadacycline treatments for ABSSSI and CABP.
ASCO 2020 Regret! Early local therapy failed to improve the overall survival rate of women with primary stage IV breast cancer
Time of Update: 2020-06-05
conclusion early local treatment cannot improve the survival rate of patients with recurrent metastatic breast cancer and IPT.
Reduce PVR by 47%! Johnson Opsumit joins her darafi phase IV clinical to reach major finish line
Time of Update: 2020-06-01
This is a forward-looking, multi-center, single-arm, open, phase IV trial that evaluates the efficacy, safety, and tolerability of Opsumit (macitentan) in combination with PDE5 inhibitor tadalafil as an initial oral treatment for newly diagnosed patients with pulmonary hypertension (PAH).
AstraZeneca announces Brilinta PHASE IV Clinical Subgroup Analysis Data
Time of Update: 2020-05-30
The data showed that in patients with high-risk coronary artery disease, Brilinta single-drug treatment reduced the risk of clinically-related bleeding for 12 months compared to aspirin-brilinta double antiplatelet therapy (DAPT), and did not increase the risk of bleeding events.
Lancet: Nivolumab for treatment of stage IV melanoma
Time of Update: 2020-05-29
studies suggest that Nivolumab single-drug or combined Ipilimumab-assisted treatment can significantly improve the non-recurrence survival rate of patients with stage IV melanoma.
College Fengyun Association (IV) Chengdu University of Traditional Chinese Medicine Beauty Association: Male President is committed to building "female
Time of Update: 2020-05-12
Sichuan news network Chengdu, June 20 (reporter He Xue) hot June, college enrollment season hot hit. When candidates choose to university , the hardware and software conditions on campus are important references. As the first and most
CR Shuanghe submits the application for import registration of Korean LG life DPP-IV hypoglycemic drug lc-15-0444
Time of Update: 2020-04-03
South Korean LG new hypoglycemic drug distributed by China Resources Shuanghe has submitted an application for registration of imported drugs.
Phase IV clinical application of Yikai tablet (pancreatic kininogenase enteric coated tablet), a key product of Qianhong pharmaceutical
Time of Update: 2020-04-03
Haitao, marketing director of Changzhou Qianhong Biochemical Pharmaceutical Co., Ltd., said in the investigation that the company's main product, Yikai tablet (Pancreatic Kallidinogenase enteric coated tablet), had started phase IV clinical treatment recently.
Cancer individualized vaccine! Tlpldc has a strong therapeutic effect on stage IV melanoma, with a disease-free survival rate of 73% in 24 months!
Time of Update: 2020-02-08
February 8, 2020 / BIOON / -- Elios therapeutics is a biopharmaceutical company dedicated to developing innovative individual therapeutic cancer vaccine